Retevmo (selpercatinib) for the Treatment of RET-Driven Cancers
RetevmoTM (selpercatinib) is the first therapy specifically indicated for the treatment of patients with advanced RET-driven lung and thyroid cancers. Credit: Shutterstock.
Learn more
Hover over the logos to learn more about the companies who made this project possible.
-
VaLea Clinical Trials
VaLea Clinical Trials specialises in providing convenient patient-centric services for...
About
VaLea Clinical Trials specialises in providing convenient patient-centric services for clinical trials in the home or alternate-site settings, based in Vienna, Austria.
FollowMake an Enquiry
-
Cellular Technology Limited
Cellular Technology Limited (CTL) is a global biotechnology company specialized...
About
Cellular Technology Limited (CTL) is a global biotechnology company specialized in the development, use, and manufacture of standardized tools for cellular immune assays.
FollowMake an Enquiry
-
SynapCon
SynapCon specialises in the development of innovative software solutions for...
About
SynapCon specialises in the development of innovative software solutions for clinical trial and medical research project management.
FollowMake an Enquiry